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A b s t r a c t
Background: Glucometabolic status (GS) in patients with acute myocardial infarction (AMI) has an impact on prognosis, but 
it may change over time.
Aim: To evaluate the prognosis after AMI treated invasively with respect to changes in GS assessed by oral glucose tolerance 
test at discharge and at mid-term follow-up visit (FU-visit).
Methods: Glucometabolic status was assessed by two-hour post-load glycaemia and defined as abnormal glucose tolerance 
(AGT) or normal glucose tolerance (NGT). Out of 454 in-hospital AMI survivors, 368 (81%) patients completed an FU-visit and 
were divided into four groups with respect to GS at discharge and FU-visit: group 1 — AGT at discharge and FU-visit (n = 101); 
group 2 — AGT at discharge and NGT at FU-visit (n = 48); group 3 — NGT at discharge and AGT at FU-visit (n = 114); and 
group 4 — NGT at discharge and FU-visit (n = 105). All-cause mortality was compared between groups with log-rank test.
Results: Median time from AMI to FU-visit was seven months. Median remote follow-up duration after AMI was 
31 months. Two-hour post load glycaemia was significantly higher in patients with confirmed AGT at FU-visit than in other 
groups. Mortality was higher in group 1 (11.9%) than in group 2 (2.1%; p = 0.034) and group 4 (2.9%; p = 0.009). Mortal-
ity rates between group 2 and 4 were similar (2.1% vs. 2.9%; p = 0.781). There was no significant difference in mortality 
between group 1 and group 3 (11.9% vs. 6.1%; p = 0.114). Mortality in group 3 was over two-fold higher than in group 4; 
however, this difference was statistically non-significant (6.1% vs. 2.9%; p = 0.247).
Conclusions: Prognosis for patients with confirmed AGT was unfavourable; however, patients with AGT at discharge, in 
whom GS improved, had similar mortality to subjects with persistent NGT. The major clinical implication from this study is 
the finding that reassessment of GS by repeated oral glucose tolerance test has significant prognostic value and makes initial 
risk stratification performed at discharge more reliable.
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INTRODUCTION
Glucometabolic status evaluated by two-hour post-load 
glycaemia (2h-PG) during oral glucose tolerance test (OGTT) 
has been a well-established risk factor for worse prognosis in 
patients with acute myocardial infarction (AMI) [1–4]. Newly 
detected diabetes mellitus (DM) or impaired glucose toler-
ance were associated with similar mortality to pre-hospital 
diabetes [5]. In stable patients after AMI, derangements 
in glucose metabolism defined at hospital discharge were 
shown to be transient, persistent, unchanged, or newly 
detected [6–10]. However, there are no recommendations 
on repeated OGTT in patients after AMI. Therefore, the aim 
of the presented work was to evaluate the prognosis after 
AMI treated invasively with respect to changes of glucometa-
bolic status assessed by OGTT at discharge and at mid-term 
follow-up visit (FU-visit).
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The presented analysis was a part of a single-centre, observa-
tional study prospectively enrolling AMI patients treated with 
percutaneous coronary intervention (PCI) between January 
2012 and December 2013, who survived the in-hospital 
period and were discharged to ambulatory care. Patients in 
whom DM was diagnosed before admission or discovered 
by elevated fasting glycaemia ≥ 7 mmol/L on at least two 
occasions during hospitalisation were excluded from the 
study. The study population encompassed 454 consecutive 
AMI survivors in whom OGTT was performed at hospital 
discharge. Repeated OGTT and other laboratory tests (blood 
count, fasting glycaemia, glycosylated haemoglobin, serum 
creatinine concentration with glomerular filtration rate [GFR] 
estimation, lipids) were planned as part of FU-visit on an 
outpatient basis approximately six months after AMI. OGTT 
with the use of 75 g of glucose was performed at hospital 
discharge (but not earlier than four days after AMI onset) 
and at FU-visit in patients without antidiabetic treatment. 
Moreover, at FU-visit in all patients an electrocardiogram and 
echocardiography were performed. Patients were divided 
into four study groups with respect to glucometabolic status 
at discharge and at FU-visit. Subjects were prospectively 
followed, and remote major adverse cardiovascular events 
(MACE) were recorded after the FU-visit. MACE were defined 
as the occurrence of death or any of the following events: 
recurrent myocardial infarction, repeated PCI, coronary 
artery by-pass grafting, hospitalisation for decompensated 
heart failure, or stroke.
Definitions of glucometabolic status
Group 1 consisted of patients with 2h-PG ≥ 7.8 mmol/L de-
tected at discharge and 2h-PG ≥ 7.8 mmol/L or antidiabetic 
pharmacotherapy at FU-visit.
Group 2 consisted of patients with 2h-PG ≥ 7.8 mmol/L 
detected at discharge and without antidiabetic pharmaco-
therapy at FU visit with 2h-PG < 7.8 mmol/L. 
Group 3 consisted of patients with 2h-PG < 7.8 mmol/L 
at discharge but with 2h-PG ≥ 7.8 mmol/L or antidiabetic 
pharmacotherapy at FU-visit.
Group 4 was established as a control group and con-
sisted of patients with 2h-PG < 7.8 mmol/L at discharge 
and without antidiabetic pharmacotherapy at FU-visit with 
2h-PG < 7.8 mmol/L.
Abnormal glucose tolerance (AGT) was defined as 2h-
-PG ≥ 7.8 mmol/L. Patients using antidiabetic agents at FU-visit 
were considered as having AGT. Patients without antidiabetic 
pharmacotherapy and 2h-PG < 7.8 mmol/L were classified as 
having normal glucose tolerance (NGT). Group 1 was consid-
ered as persistent AGT, group 2 as transient AGT, group 3 as 
newly detected AGT, group 4 as persistent NGT.
Definitions of AMI 
Clinical AMI criteria evaluated on admission were: chest pain 
persisting > 20 min, ST segment elevation of at least 0.1 mV 
in two or more contiguous electrocardiographic leads, or 
non-diagnostic electrocardiogram (without persistent ST seg-
ment elevation, left bundle branch block, or acute ischaemic 
changes) with enzymatic confirmation of AMI. 
Catheterisation protocol and treatment
All patients before coronary angiography received a single 
dose of oral aspirin (300 mg), loading dose of P2Y12 inhibi-
tor, just before PCI, and 100 U/kg of intravenous heparin 
(additional boluses were given as appropriate to achieve 
activated clotting time > 250 s). In all patients, coronary 
angiography and PCI of infarct-related artery were per-
formed immediately after admission. After the intervention, 
all patients received 75–100 mg of aspirin daily indefinitely, 
a maintenance dose of P2Y12 inhibitor, as well as beta-block-
ers, angiotensin-converting enzyme inhibitors/angiotensin 
receptor blockers, and statins, if these agents were not con-
traindicated. All patients with disturbances in glucose me-
tabolism were advised on lifestyle modification. Antidiabetic 
pharmacotherapy for new onset DM detected at hospital 
discharge was started after consultancy with a diabetology 
specialist. Patients with newly detected DM during FU-visit 
on repeated OGTT were referred to a diabetology specialist 
on an outpatient basis.
Ethics
All clinical data were obtained as a result of the diagnostic 
procedures and therapy, which were in accordance with 
the appropriate guidelines. All patients provided informed, 
written consent for hospitalisation, invasive treatment, 
and use of their data for research purposes. Follow-up 
visits were performed on an outpatient basis as a routine 
follow-up. Remote follow-up was performed by telephone 
contact with patients or their families as well as during 
routine ambulatory visits. The study protocol was in line 
with ethical standards and was approved by the Institutional 
Review Board.
Statistical analysis
Continuous parameters were expressed as means with standard 
deviations unless otherwise specified, and categorical variables 
were presented as numbers and percentages. Comparative 
analyses between groups were performed using Student’s t-test 
for continuous variables and c2 or Fisher’s exact test, as appropri-
ate, for dichotomous parameters. Log-rank tests were used to 
compare Kaplan-Meier curves plotted for cumulative survival. All 
tests were double-sided. P value < 0.05 was considered statisti-
cally significant. All analyses were performed using the software 
package Statistica (version 6.1, StatSoft Inc., Tulsa, OK, USA). 
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The analysis of receiver-operator characteristic (ROC) 
curves was performed using MedCalc (version 11.3.0.0, 
MedCalc, Ostend, Belgium).
RESULTS 
Out of 454 in-hospital AMI survivors with OGTT at discharge, 
368 (81.0%) patients completed FU-visit with laboratory 
re-evaluation of glucometabolic status. For all patients, remote 
follow-up was obtained. The median time to FU-visit was 
seven months. The median remote follow-up duration after 
AMI was 31 months. Four (0.9%) patients died before FU-visit. 
All survivors to the FU-visit were encouraged to participate in 
the visit; however, 82 (18.1%) patients refused and thus were 
considered lost to follow-up. Out of all patients who com-
pleted FU-visit, 353 (95.9%) had re-evaluated glucometabolic 
status with OGTT. Fifteen patients in whom OGTT was not 
repeated were treated with antidiabetic pharmacotherapy. 
The enrolment of patients into the study is shown in Figure 1.
Comparative analysis of demographic,  
clinical, laboratory, and pharmacotherapy  
data obtained at follow-up visit 
Patients with persistent AGT, when compared to the control 
group, were older, more often had a history of atrial fibril-
lation/flutter (AF/AFL) and pre-hospital history of arterial 
hypertension, had lower estimated GFR, higher concentration 
of triglycerides, and were more often treated with dihydro-
pyridine calcium channel blocker or diuretic.
Patients with transient AGT, when compared to the 
control group, more often had a history of AF/AFL, had 
lower estimated GFR, and were more often treated with 
angiotensin converting enzyme inhibitor or angiotensin II 
receptor antagonist.
Patients with newly detected AGT, when compared to 
the control group, more often had a history of AF/AFL and 
had higher concentration triglycerides.
Triglyceride concentration was higher in groups with AGT 
at FU-visit than in the control group.
Comparative analysis glucometabolic  
data and markers of myocardial injury 
Obesity was diagnosed during hospitalisation most frequently 
within the group with persistent AGT at FU-visit, but there 
were no statistically significant differences in the prevalence 
of obese patients between study groups. In-hospital admis-
sion glycaemia was significantly higher in group with transient 
or persistent AGT compared to groups with newly detected 
AGT or persistent NGT. The difference between persistent 
AGT and transient AGT was not significant (p = 0.103). 
In-hospital fasting glycaemia was significantly higher in group 
with persistent AGT compared to all other groups. At FU-visit, 
fasting glycaemia was significantly higher in all study groups 
when compared to the control group, but there were no 
significant differences between study groups. Two-hour post 
load glycaemia during OGTT performed in-hospital and at 
FU-visit was significantly higher in patients with persistent 
AGT than in other groups. 
Patients with transient AGT had the highest concentra-
tions of highly sensitive troponin T and MB isoenzyme of cre-
atine kinase (CK-MB); however, the only statistically significant 
difference was observed between groups 2 and 3 with respect 
to CK-MB value. There was a trend towards significantly higher 
CK-MB in group 2 than in the control group (p = 0.056). 
Detailed characteristics of particular study groups are 
presented in Tables 1 and 2.
The analysis of ROC curves
Receiver-operator characteristic curve analysis was performed 
to assess the diagnostic accuracy of in-hospital admission gly-
caemia, fasting glycaemia, and 2h-PG, which were measured 
during index hospitalisation for the prediction of sustained 
AGT or newly detected AGT at FU-visit. In patients with AGT 
Figure 1. Patient enrolment into the study; 2h-PG — two-hour post load glucose; AMI — acute myocardial infarction;  
FU — follow-up; OGTT — oral glucose tolerance test
454 AMI survivors with OGTT at discharge
183 patients with 2h-PG  7.8 mmol/L 271 patients with 2h-PG < 7.8 mmol/L
3 patients died 1 patient died
31 lost to FU 51 lost to FU
GROUP 1 GROUP 2 
101 patients with 
antidiabetic treatment 
or 2h-PG  7.8 mmol/L 
at FU 
48 patients without 
antidiabetic treatment 
or 2h-PG < 7.8 mmol/L 
at FU 
105 patients without 
antidiabetic treatment 
or 2h-PG < 7.8 mmol/L 
at FU
GROUP 4GROUP 3 
114 patients with 
antidiabetic treatment 
or 2h-PG  7.8 mmol/L 
at FU 
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Table 1. Comparative analysis of glucometabolic data and markers of myocardial injury
Patients’ characteristics Group 1  
(n = 101)
Group 2  
(n = 48)
Group 3  
(n = 114)
Group 4  
(n = 105)
In-hospital diagnosis of obesity (BMI ≥ 30 kg/m2) 32 (31.7%) 12 (25.0%) 26 (22.8%) 23 (21.9%)
In-hospital admission glycaemia [mmol/L] 7.86 ± 2.05a, c 7.28 ± 1.95a, d 6.47 ± 1.44 6.55 ± 1.68
In-hospital fasting glycaemia [mmol/L] 6.0 ± 0.87a, b, c 5.6 ± 0.71 5.43 ± 0.55 5.4 ± 0.59
In-hospital 2-hour post-load glycaemia [mmol/L] 10.58 ± 2.23a, b, c 9.27 ± 1.3a, d 6.47 ± 1.11 6.52 ± 1.1
Fasting glycaemia at FU-visit [mmol/L] 6.0 ± 0.85a 5.77 ± 0.57a 5.84 ± 0.69a 5.57 ± 0.62
2-h post-load glycaemia at FU-visit [mmol/L] 9.58 ± 1.84*, a, b, c 6.02 ± 2.02d 8.83 ± 1.59a 5.74 ± 1.88
Glycosylated haemoglobin at FU-visit [%] 6.16 ± 0.52a, b, c 5.7 ± 0.35d 6.01 ± 0.37a 5.7  ± 0.47
TnT-hs [ng/mL] 1.49 ± 2.34 1.69 ± 2.48 1.31 ± 2.18 1.51 ± 2.37
CK-MB [ng/mL] 117.17 ± 147.38 151.09 ± 150.78d, e 94.41 ± 118.18 107.33 ± 120.06
Values presented as means ± standard deviation or number and percentage of subjects; AGT — abnormal glucose tolerance; BMI — body mass 
index; CK-MB — creatine kinase-MB isoenzyme; FU-visit — follow-up ambulatory visit; NGT — normal glucose tolerance; Group 1 — AGT at dis-
charge and FU-visit; Group 2 — AGT at discharge but NGT at FU-visit; Group 3 — NGT at discharge but AGT at FU-visit; Group 4 — NGT at  
discharge and FU-visit; NGT — normal glucose tolerance; TnT-hs — troponin T high sensitive assay; ap < 0.05 vs. group 4; bp < 0.05 — group 1  
vs. group 2; cp < 0.05 — group 1 vs. group 3; dp < 0.05 — group 2 vs. group 3; etrend towards significant difference between group 2 and 
group 4 (p = 0.056); *values obtained during oral glucose tolerance test in patients without antidiabetic treatment
Table 2. Comparative analysis of demographic, clinical, laboratory, and pharmacotherapy data obtained at follow-up visit
Patients’ characteristics at FU-visit Group 1  
(n = 101)
Group 2  
(n = 48)
Group 3  
(n = 114)
Group 4  
(n = 105)
Age [years] 64.8 ± 9.2a, c 62.2 ± 9.2 61.4 ± 9.3 59.7 ± 10.6
Female sex 26 (25.7%) 14 (29.2%) 28 (24.6%) 25 (23.8%)
Pre-hospital history of arterial hypertension 77 (76.2%)a, c 30 (62.5%) 69 (60.5%) 57 (54.3%)
Left ventricle ejection fraction [%] 46.36 ± 9.44 46.1 ± 8.3 48 ± 6.5 48 ± 7.97
eGFR [mL/min/1.73 m2] 82.7 ± 26.9a 83.9 ± 18.8a 87.89 ± 18.23 92 ± 22.5
Haemoglobin [mmol/L] 8.72 ± 0.81 8.98 ± 0.77 8.85 ± 0.86 8.86 ± 0.92
Atrial fibrillation/flutter 14 (13.9%)a 8 (16.6%)a 9 (7.9%)a 2 (1.9%)
HDL cholesterol [mmol/L] 1.28 ± 0.39 1.36 ± 0.37 1.29 ± 0.46 1.35 ± 0.38
LDL cholesterol [mmol/L] 2.44 ± 0.87c 2.58 ± 0.94 2.73 ± 1.2 2.53 ± 0.93
Triglycerides [mmol/L] 1.46 ± 1a 1.31 ± 0.6 1.46 ± 0.94a 1.23 ± 0.6
Acetylsalicylic acid 94 (93.1%) 44 (91.7%) 104 (91.2%) 102 (97.1%)
P2Y12 receptor inhibitor 100 (99%)
c 46 (95.8%) 105 (92.1%) 104 (99%)
Beta-adrenergic blocker 100 (97%) 45 (93.7%) 110 (96.5%) 98 (93.3%)
ACE-I/ARB 95 (94.1%) 48 (100%)a, d 102 (89.5%) 93 (88.6%)
Statin 95 (94.1%) 46 (95.8%) 109 (95.6%) 99 (94.3%)
Dihydropyridine CCB 28 (27.7%)a 12 (25%) 23 (20.2%) 17 (16.2%)
Diuretic 43 (42.6%)a, c 13 (27.1%) 26 (22.8%) 17 (16.2%)
Aldosterone receptor antagonist 33 (32.7%)c 13 (27.1%) 22 (19.3%) 23 (22.1%)
Antidiabetic pharmacotherapy 15 (14.9%) 0 (0%) 0 (0%) 0 (0%)
Oral hypoglycaemic agent 13 (12.9%) – – –
Metformin 9 (8.9%) – – –
Insulin 2 (2%) – – –
Values presented as means ± standard deviation or number and percentage of subjects; eGFR — estimated glomerular filtration rate; FU-visit — 
follow-up ambulatory visit; HDL — high-density lipoprotein; LDL — low-density lipoprotein; ACE-I — angiotensin converting enzyme inhibitor; 
ARB — angiotensin II receptor antagonist; CCB — calcium channel blocker; ap < 0.05 vs. group 4; bp < 0.05 — group 1 vs. group 2; cp < 0.05 
— group 1 vs. group 3; dp < 0.05 — group 2 vs. group 3
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at discharge, in-hospital fasting glycaemia and in-hospital 
2h-PG discriminated between AGT and NGT at FU-visit. The 
highest value of area under the curve (AUC) was observed 
for 2h-PG (AUC = 0.677). In patients with NGT at discharge 
none of the analysed glycaemic parameters during hospitalisa-
tion had the ability to distinguish between AGT and NGT at 
FU-visit. The results of ROC analysis are presented in Figure 2.
Comparative analyses of mortality  
and adverse cardiovascular events
Among patients who completed FU-visit, there was no statisti-
cally significant difference in mortality between patients with 
AGT and subjects with NGT determined at hospital discharge 
(8.7% vs. 4.6%; p = 0.111). There was a trend towards more 
MACE after FU-visit in patients with AGT at discharge (24.2% 
vs. 16%; p = 0.051). However, there were statistically sig-
nificant differences in mortality rates between study groups 
with respect to glucometabolic status re-evaluated at FU-visit. 
Mortality was higher in group with persistent AGT (11.9%) than 
in group with transient AGT (2.1%; p = 0.034) and control 
group (2.9%; p = 0.009). Mortality rates between group 2 
and 4 were similar (2.1% vs. 2.9%; p = 0.781). There was no 
significant difference in mortality between group 1 and group 3 
although it was almost two-fold higher (11.9% vs. 6.1%; 
p = 0.114). Mortality in group with newly detected AGT 
was over two-fold higher than in group with persistent NGT; 
however, this difference was non-significant (6.1% vs. 2.9%; 
p = 0.247). Comparative analysis of mortality rates between 
groups are presented in Figure 3.
Analysis of MACE showed higher incidence of events in 
group 1 (24.8%) and group 2 (22.9%) than in group 3 (16.7%) 
and group 4 (15.2%); however, those differences were not 
statistically significant. Comparative analysis of prognosis 
between study groups is shown in Table 2.
Among 15 patients who were treated with antidiabetic 
drugs (all subjects in group 1) one major adverse event oc-
curred, and there were no deaths during remote follow-up. 
DISCUSSION
Initial data had indicated that the prognosis in patients with 
AGT was significantly determined in the early post-infarction 
period, but more recent studies have shown that AGT is also 
Figure 2. The analysis of receiver-operator characteristic (ROC) curves of in-hospital glycaemic parameters for the prediction of 
persistent abnormal glucose tolerance (AGT) at follow-up ambulatory visit (FU-visit) among patients with AGT at discharge (A) 
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associated with worse long-term outcome [1–4]. In the pre-
sented work, among patients without pre-hospital DM, who 
completed FU-visit, risk stratification with respect to glucometa-
bolic status when performed at hospital discharge revealed no 
significant differences in remote mortality between AGT and 
NGT. However, patients with persistent AGT at FU-visit had 
significantly higher all-cause mortality than patients with AGT 
at discharge, who improved glucometabolic profile. Transient 
AGT was associated with similar mortality to persistent NGT. 
Those observations may be partially explained in relation to 
conclusions from the study published by Perreault et al. [11], 
who showed that in patients with prediabetes, conversion to 
normal glucose regulation, even if transient, was associated 
with lower long-term cardiovascular risk. The presented study 
showed that patients with newly detected AGT at FU-visit 
had over two-fold higher mortality than controls and almost 
two-fold lower than patients with confirmed AGT; however, the 
observed differences were statistically non-significant. Henareh 
et al. [6] showed, that in stable patients who were evaluated 
for new onset glucose abnormalities several months after AMI, 
there were no differences in long-term cardiovascular outcome 
between patients with AGT and NGT, although increase in 
two-hour post load glucose had an adverse impact on prognosis 
[6]. Conversely, in patients with stable coronary artery disease 
during a median observation of 4.3 years, new onset AGT was 
associated with worse prognosis, including mortality [12]. In 
light of published data and the observed divergence in survival 
curves presented in Figure 2, it is likely that higher mortality in 
patients with newly detected AGT would become significant 
during a longer follow-up period.
An important finding from this study was that in patients 
with AGT at discharge in-hospital fasting glycaemia and 
particularly 2h-PG were useful parameters for the prediction 
of AGT at FU-visit. In the-long term observation, admission 
glycaemia was not a reliable risk factor of mortality in relation 
to glucometabolic status; however, patients with transient AGT 
appeared to have an increased risk of non-fatal MACE when 
compared to newly detected AGT and controls with persis-
Table 3. Comparative analysis between groups with respect to all-cause mortality and major adverse cardiovascular events 
(MACE) during remote follow-up after follow-up visit
Adverse events Group 1 (n = 101) Group 2 (n = 48) Group 3 (n = 114) Group 4 (n = 105)
All-cause mortality 12 (11.9%)a, b 1 (2.1%) 7 (6.1%) 3 (2.9%)
MACE* 25 (24.8%) 11 (22.9%) 19 (16.7%) 16 (15.2%)
Values presented as number and percentage of subjects; *Each event was counted only once; ap < 0.05 vs. group 4; bp < 0.05 — group 1 vs. 
group 2
Figure 3. Kaplan-Meier curves for cumulative survival in patients with acute myocardial infarction (AMI) with respect to gluco-
metabolic status at follow-up visit; Group 1 — AGT at discharge and FU-visit; Group 2 — AGT at discharge but NGT at FU-visit; 
Group 3 — NGT at discharge but AGT at FU-visit; Group 4 — NGT at discharge and FU-visit; AGT — abnormal glucose tolerance; 
NGT — normal glucose tolerance; FU-visit — follow-up ambulatory visit
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tent NGT. This observation could be interpreted according 
to the results of the study by Timmer et al. [13], who showed 
that in patients without pre-hospital DM, after exclusion of 
early mortality (within 30 days), admission glycaemia lost its 
significant impact on long-term mortality, although this pa-
rameter was associated with larger infarct size. The association 
of acute hyperglycaemia with infarct size has been shown 
recently, especially in patients without evidence of chronic 
hyperglycaemia [14]. Those data correspond with observed 
differences in admission glycaemia and CK-MB levels between 
study groups. Patients with a transient pattern of AGT had sig-
nificantly higher admission glycaemia and enzymatic evidence 
of larger infarct size than patients with new onset AGT or 
persistent NGT. Considering the cited studies, it is reasonable 
to assume that a transient pattern of AGT is related to a larger 
infarct size, haemodynamic stress, and acute hyperglycaemia. 
Whether patients who recovered to NGT at FU-visit would 
eventually develop glucose abnormalities is not known.
Clinical implications
The major clinical implication from this study is the find-
ing that reassessment of glucometabolic status by repeated 
OGTT has significant prognostic value and makes initial risk 
stratification performed at discharge more reliable. However, 
the optimal secondary prevention strategy in patients with 
new onset glucose abnormalities and AMI still has not been 
thoroughly established. Although nonpharmacological treat-
ment is considered the first-line therapy for new onset glucose 
abnormalities, published studies have shown unsatisfactory 
adherence to such management in patients with coronary 
artery disease, especially with concomitant DM [12, 15–17]. 
Recently, it has been shown that among patients with ST el-
evation myocardial infarction and without DM, but including 
patients with prediabetes, subjects who were treated with 
metformin presented modest improvement of cardiovascular 
risk profile at four-month follow-up [18]. Anselmino et al. [19] 
showed that there was a pronounced decrease in cardiovas-
cular events in patients with newly detected DM, who were 
prescribed glucose lowering drugs, compared with those not 
receiving such treatment.
Published data indicated also that pharmacological and 
nonpharmacological management of patients with impaired 
glucose tolerance had favourable cardiovascular effects 
[20–22].
Limitations of the study
The study was nonrandomised and observational. It encom-
passed consecutive patients who were hospitalised due to 
AMI; however, not all subjects who were discharged partici-
pated in FU-visits. Thus, it is likely that patients who were 
evaluated at the visit had higher levels of compliance and 
more favourable risk profiles than the remaining subjects. It 
suggests that glucometabolic status after AMI was not reflected 
adequately. There were no data on cross-over between study 
groups or the initiation of glucose-lowering medication during 
remote follow-up after the FU-visit. The authors were unable 
to receive data on the mechanism of all deaths. It is well 
known that, in addition to vascular disease, DM and predia-
betes are associated with mortality also due to other causes 
[23, 24]. However, the comparisons between study groups 
and other studies with respect to cardiac deaths are missing.
CONCLUSIONS
In patients who completed FU-visit at the mid-term period 
after AMI, reassessment of glucometabolic status by OGTT 
improved long-term risk stratification. Persistent AGT at 
FU-visit was associated with significantly higher all-cause 
mortality than transient AGT or sustained NGT. Patients with 
AGT at discharge in whom glucometabolic profile improved 
had similar mortality to subjects with persistent NGT.
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Rokowanie długoterminowe jest zależne  
od zmian stanu glukometabolicznego  
w obserwacji średnioterminowej u pacjentów  
z zawałem serca leczonych inwazyjnie 
Paweł Francuz, Tomasz Podolecki, Katarzyna Przybylska-Siedlecka, Zbigniew Kalarus, Jacek Kowalczyk
Oddział Kliniczny Kardiologii Katedry Kardiologii, Wrodzonych Wad Serca i Elektroterapii, Śląski Uniwersytet Medyczny,  
Śląskie Centrum Chorób Serca, Zabrze
S t r e s z c z e n i e
Wstęp: Metabolizm glukozy u pacjentów z zawałem serca (MI) ma znaczenie rokownicze, jednak może zmieniać się po 
ostrej fazie choroby.
Cel: Celem pracy było określenie znaczenia rokowniczego zmian metabolizmu glukozy wykrytych na podstawie doustnego 
testu obciążenia glukozą wykonanego przy wypisywaniu ze szpitala oraz podczas wizyty kontrolnej u chorych leczonych 
inwazyjnie w ostrej fazie MI.
Metody: Stan metaboliczny określono na podstawie glikemii po 2 godzinach od obciążenia glukozą jako nieprawidłowa 
tolerancja glukozy lub prawidłowa tolerancja glukozy. Spośród 454 pacjentów, którzy przeżyli okres wewnątrzszpitalny, 
w wizytach kontrolnych uczestniczyło 368 (81%) chorych, którzy zostali podzieleni na cztery grupy w zależności od stanu 
metabolicznego określonego przy wypisywaniu ze szpitala i podczas wizyty kontrolnej: grupa 1 — nieprawidłowa tolerancja 
glukozy przy wypisywaniu ze szpitala i podczas wizyty kontrolnej (n = 101); grupa 2 — nieprawidłowa tolerancja glukozy 
przy wypisywaniu ze szpitala i prawidłowa podczas wizyty kontrolnej (n = 48); grupa 3 — prawidłowa tolerancja glukozy 
przy wypisywaniu ze szpitala i nieprawidłowa podczas wizyty kontrolnej (n = 114); grupa 4 — prawidłowa tolerancja glukozy 
przy wypisywaniu ze szpitala oraz podczas wizyty kontrolnej (n = 105). Śmiertelność całkowita została porównana między 
grupami przy użyciu testu log-rank. 
Wyniki: Mediana czasu do wizyty kontrolnej wyniosła 7 miesięcy. Mediana czasu całkowitej obserwacji po MI — 31 miesię-
cy. Podczas wizyty kontrolnej glikemia po 2 godzinach od obciążenia glukozą była znamiennie wyższa w grupie pacjentów 
z potwierdzoną nieprawidłową tolerancją glukozy niż w pozostałych grupach badanych. Śmiertelność była wyższa w grupie 1  
(11,9%) niż w grupie 2 (2,1%; p = 0,034), jak również w grupie 1 niż w grupie 4 (2,9%; p = 0,009). Rokowanie pacjentów 
w grupie 2 i w grupie 4 było podobne (2,1% vs. 2,9%; p = 0,781). Śmiertelność w grupie 1 była prawie 2-krotnie wyższa niż 
w grupie 3 (11,9% vs. 6,1%; p = 0,114), a w grupie 3 ponad 2-krotnie wyższa niż w grupie 4 (6,1% vs. 2,9%; p = 0,247), 
jednak różnice te nie były istotnie statystycznie.
Wnioski: Rokowanie pacjentów, u których podczas wizyty kontrolnej potwierdzono nieprawidłową tolerancję glukozy, było 
gorsze niż w pozostałych grupach badanych. Pacjenci, u których przy wypisywaniu ze szpitala stwierdzono nieprawidłową 
tolerancję glukozy, jeżeli poprawili profil metaboliczny, mieli podobne rokowanie do osób z potwierdzoną prawidłową tole-
rancją glukozy. Otrzymane wyniki mają znaczenie kliniczne, ponieważ wskazują, że ponowna ocena stanu metabolicznego 
na podstawie doustnego testu obciążenia glukozą u chorych po MI poprawia i wzmacnia stratyfikację ryzyka wykonaną przy 
wypisywaniu ze szpitala. 
Słowa kluczowe: doustny test obciążenia glukozą, nieprawidłowa tolerancja glukozy, śmiertelność, zawał serca
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